Molecular genetics of Ewing sarcoma, model systems and finding novel (immuno-) therapeutic targets

Abstract

Ewing sarcoma (EWS) is a bone- and soft tissue tumour affecting primarily children and young adults. A quarter of patients present with metastases at the time of diagnosis and have a poor outlook in terms of overall survival. Efforts are made across the field to gain deeper insight in the genetics of this enigmatic neoplasm. EWS is characterized by presence of an oncogenic translocation gene, EWSR1-ETS. In addition, there are a limited number of known recurrent DNA copy number variations and mutations. Subsequent of the above, the epigenetic profile of EWS is subject of interest. In this review, we summarize the current available knowledge on the genetics underpinning EWS, explore the current knowledge of its epigenetic profile, discuss in vitro and in vivo model systems, and explore the unravelling knowledge of potential targets for treatment including recent insights into potential immunotherapy.

Keywords

Bone neoplasm / Ewing sarcoma / genetic translocation / DNA copy number variation / mutation

References

[1] Fletcher CDM,Hogendoorn PCW.WHO classification of tumours of soft tissue and bone, 4th ed.2013;Lyon, FranceIARC Press

[2] Ewing J.Diffuse endothelioma of bone.Proc N Y Path1921;21:17-24

[3] Lizard-Nacol S,Justrabo E.Immunologic characterization of Ewing's sarcoma using mesenchymal and neural markers.Am J Pathol1989;135:847-55 PMCID:PMC1880093

[4] Maurer HM.Solid tumors in children.N Engl J Med1978;299:1345-8

[5] Toomey EC,Lessnick SL.Recent advances in the molecular pathogenesis of Ewing's sarcoma.Oncogene2010;29:4504-16 PMCID:PMC3555143

[6] Geens L,Geert V.An unusual location of extraosseous Ewing's sarcoma.Case Rep Oncol2013;6:293-302 PMCID:PMC3725030

[7] Pizzo PA.Principles and Practice of Pediatric Oncology, 6th ed.2011;Philadelphia, United StatesWolters Kluwer Health/Lippincott Williams & Wilkins

[8] Bacci G,Longhi A,De Paolis M,Versari M,Briccoli A.Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997.Ann Oncol2003;14:1654-9

[9] Meyers PA,Ladanyi M,Sailer SL,Baker DL,Gerbing RB,Herzog CE,Liu-Mares W,Sieger L,Gorlick RG.High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.J Clin Oncol2001;19:2812-20

[10] Bernstein M,Paulussen M,Schuck A,Juergens H.Ewing's sarcoma family of tumors: current management.Oncologist2006;11:503-19

[11] Balamuth NJ.Ewing's sarcoma.Lancet Oncol2010;11:184-92

[12] Hamilton SN,Hasan H,Goddard K.Long-term outcomes and complications in pediatric Ewing sarcoma.Am J Clin Oncol2017;40:423-8

[13] Paulussen M,Burdach S,Dockhorn-Dworniczak B,Fröhlich B,Zoubek A.Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies.European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol1998;9:275-81

[14] Miser JS,Tarbell NJ,Fryer CJ,Gebhardt MC,Perlman EJ,Donaldson SS,Rausen AR,Grier HE.Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.J Clin Oncol2004;22:2873-6

[15] Drabko K,Bilska K,Ussowicz M,Wojcik B,Gorczynska E,Wozniak W,Wysocki M,Kowalczyk J.Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma.Bone Marrow Transplant2012;47:1530-4

[16] Ladenstein R,Le Deley MC,Paulussen M,van den Berg H,Hjorth L,Lewis I,Jürgens H.Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.J Clin Oncol2010;28:3284-91

[17] Juergens C,Lewis I,Paulussen M,Michon J,Juergens H.Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial..Pediatr Blood Cancer2006;47:22-9

[18] Bailly RA,Zucman J,Delattre O,Thomas G.DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma.Mol Cell Biol1994;14:3230-41 PMCID:PMC358690

[19] Zucman J,Desmaze C,Plougastel B,Zucker JM,Sheer D.Combinatorial generation of variable fusion proteins in the Ewing family of tumours.EMBO J1993;12:4481-7 PMCID:PMC413872

[20] Sorensen PH,Lopez-Terrada D,Triche TJ.A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG.Nat Genet1994;6:146-51

[21] Ohno T,Reddy ES.EWS/Fli-1 chimeric protein is a transcriptional activator.Cancer Res1993;53:5859-63

[22] Arvand A.Biology of EWS/ETS fusions in Ewing's family tumors.Oncogene2001;20:5747-54

[23] Sankar S,Bearss J,Hoffman LM,Beckerle MC,Lessnick SL.Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.Clin Cancer Res2014;20:4584-97 PMCID:PMC4155010

[24] Tomazou EM,Schmidl C,Schönegger A,Kubicek S,Kovar H.Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1.Cell Rep2015;10:1082-95 PMCID:PMC4542316

[25] Tanabe Y,Kohsaka S,Akaike K,Kurihara T,Okubo T,Kazuno S,Saito T.IRE1α-XBP1 inhibitors exerted anti-tumor activities in Ewing's sarcoma.Oncotarget2018;9:14428-43 PMCID:PMC5865680

[26] Selvanathan SP,Erkizan HV,Natarajan TG,Yu S,Paulsen MT,Wu CH,üren A.Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.Proc Natl Acad Sci U S A2015;112:E1307-16 PMCID:PMC4371969

[27] Svoboda LK,Sud S,Zebolsky A,Thomas D,Lee HJ,Zhang L,Bankhead AR,Ljungman M,Grembecka J,Lawlor ER.Menin regulates the serine biosynthetic pathway in Ewing sarcoma.J Pathol2018;

[28] Kedage V,Nicholas TR,Plotnik JP,Hollenhorst PC.An interaction with Ewing's sarcoma breakpoint protein EWS defines a specific oncogenic mechanism of ETS factors rearranged in prostate cancer.Cell Rep2016;17:1289-301 PMCID:PMC5123826

[29] Lin PP,Hamelin AC,Healey JH.Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.Cancer Res1999;59:1428-32

[30] de Alava E,Antonescu CR,Pardo-Mindán FJ,Ladanyi M.Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.Am J Pathol2000;156:849-55

[31] Le Deley MC,Schaefer KL,Koehler G,Lion T,Marandet J,Pierron G,Nesslböck M,Dirksen U,Lewis IJ,Jürgens H.Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial..J Clin Oncol2010;28:1982-8

[32] Grohar PJ,Rangel Rivera GO,Haddock S,Maloney NK,O'Neill M,Huppi K,Gehlhaus K,Buehler E,Martin SE.Functional genomic screening reveals splicing of the EWS-FLI1 fusion transcript as a vulnerability in Ewing sarcoma.Cell Rep2016;14:598-610 PMCID:PMC4755295

[33] Minas TZ,Javaheri T,Howarth M,Han J,Sax B,Hong SH,Tirode F,Toretsky JA,Kovar H,Sweet-Cordero EA,Moriggl R,üren A.Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model.Oncotarget2017;8:34141-63 PMCID:PMC5470957

[34] Postel-Vinay S,Tirode F,Reynaud S,Oberlin O,Ballet S,Kontny U,Picci P,Patino-Garcia A,Laud K,Froguel P,Doz F,Chanock SJ,Cox DG.Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma.Nat Genet2012;44:323-7

[35] Grünewald TG,Gilardi-Hebenstreit P,Surdez D,Mirabeau O,Tirode F,Perot G,Lucchesi C,Oberlin O,Véron AS,Lapouble E,Rio Frio T,Bhatia S,Cancel-Tassin G,Cox DG,Machiela MJ,Charnay P.Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.Nat Genet2015;47:1073-8 PMCID:PMC4591073

[36] Gangwal K,Hollenhorst PC,Haroldsen SC,Boucher KM,Jorde LB,Lessnick SL.Microsatellites as EWS/FLI response elements in Ewing's sarcoma.Proc Natl Acad Sci U S A2008;105:10149-54 PMCID:PMC2481306

[37] Guillon N,Boeva V,Barillot E.The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function.PLoS One2009;4:e4932 PMCID:PMC2654724

[38] Kawamura-Saito M,Kaneko K,Kanda H,Gotoh T,Fukayama M,Takizawa T.Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation.Hum Mol Genet2006;15:2125-37

[39] Pierron G,Lucchesi C,Ballet S,Perrin V,Delattre O.A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion.Nat Genet2012;44:461-6

[40] Jeon IS,Braun BS,Roussel MF,Shapiro DN.A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.Oncogene1995;10:1229-34

[41] Urano F,Yabe H,Yoshida K,Hata J.Molecular analysis of Ewing's sarcoma: another fusion gene, EWS-E1AF, available for diagnosis.Jpn J Cancer Res1998;89:703-11 PMCID:PMC5921883

[42] Peter M,Pacquement H,Thomas G,Delattre O.A new member of the ETS family fused to EWS in Ewing tumors.Oncogene1997;14:1159-64

[43] Shing DC,Roberts P,Chin SF,Tillman RM,Cullinane C.FUS/ERG gene fusions in Ewing's tumors.Cancer Res2003;63:4568-76

[44] Ng TL,Pallen CJ,Clarkson PW,Sorensen PH,Horsman DE.Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV.J Mol Diagn2007;9:459-63 PMCID:PMC1975098

[45] Szuhai K,de Jong D,Tanke HJ.The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology.Clin Cancer Res2009;15:2259-68

[46] Yamaguchi S,Ishikawa Y,Mukai H.EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12)..Genes Chromosomes Cancer2005;43:217-22

[47] Sumegi J,Nelson M,Perry D.A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor.Mod Pathol2011;24:333-42

[48] Mastrangelo T,Tornielli S,Testi MA,Radice P,Pilotti S,Pierotti MA.A novel zinc finger gene is fused to EWS in small round cell tumor.Oncogene2000;19:3799-804

[49] Wang L,Zheng T,Collins MH,Ladanyi M.Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions.J Mol Diagn2007;9:498-509 PMCID:PMC1975108

[50] Brohl AS,Chang W,Song Y,Patidar R,Chen L,Liao H,Gerard J,Lopez Guerrero JA,Wai DH,Triche T,Miettinen M,Catchpool D,Waldman T.The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation.PLoS Genet2014;10:e1004475 PMCID:PMC4091782

[51] Sugita S,Tonooka A,Totoki Y,Aoyama T,Tsukahara T,Shibata T.A novel CIC-FOXO4 gene fusion in undifferentiated small round cell sarcoma: a genetically distinct variant of Ewing-like sarcoma.Am J Surg Pathol2014;38:1571-6

[52] Specht K,Sung YS,Dry S,Richter GH,Antonescu CR.Novel BCOR-MAML3 and ZC3H7B-BCOR gene fusions in undifferentiated small blue round cell sarcomas.Am J Surg Pathol2016;40:433-42 PMCID:PMC4792719

[53] Alholle A,Brini AT,Kannappan V,Niblett A,Pissaloux D,Maran-Gonzalez A,Sumathi V,Latif F.Genetic analyses of undifferentiated small round cell sarcoma identifies a novel sarcoma subtype with a recurrent CRTC1-SS18 gene fusion.J Pathol2018;245:186-96

[54] Mugneret F,Aurias A.Chromosomes in Ewing's sarcoma.II. Nonrandom additional changes, trisomy 8 and der(16)t(1;16). Cancer Genet Cytogenet1988;32:239-45

[55] Armengol G,Virolainen M,Valle J,Asko-Seljavaara S,Elomaa I,Kivioja AH,Tukiainen E,Myklebost O.Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization.Br J Cancer1997;75:1403-9 PMCID:PMC2223493

[56] Maurici D,Grier HE,Serra M.Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma.Cancer Genet Cytogenet1998;100:106-10

[57] Hattinger CM,Ambros IM,Lion T,Gadner H.Demonstration of the translocation der(16)t(1;16)(q12;q11.2) in interphase nuclei of Ewing tumors..Genes Chromosomes Cancer1996;17:141-50

[58] Hattinger CM,Tarkkanen M,Zielenska M,Kager L,Knuutila S,Ambros PF,Betts DR.Prognostic impact of chromosomal aberrations in Ewing tumours.Br J Cancer2002;86:1763-9 PMCID:PMC2375399

[59] Brisset S,Peter M,Oberlin O,Aurias A.CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases.Cancer Genet Cytogenet2001;130:57-61

[60] Douglass EC,Valentine M,Meyer WH.A second nonrandom translocation, der(16)t(1;16)(q21;q13), in Ewing sarcoma and peripheral neuroectodermal tumor.Cytogenet Cell Genet1990;53:87-90

[61] Sandberg AA.Updates on cytogenetics and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors.Cancer Genet Cytogenet2000;123:1-26

[62] Mackintosh C,García-Domínguez DJ,Llombart-Bosch A,Scotlandi K,Sciot R,Hogendoorn PC,Knuutila S,Debiec-Rychter M,de álava E.1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.Oncogene2012;31:1287-98

[63] Savola S,Tripathi A,Serra M,Kaski S,Scotlandi K.Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors.BMC Cancer2009;9:17 PMCID:PMC2633345

[64] Tirode F,Ma X,Le Deley MC,Zhang Z,Grossetête-Lalami S,Reynaud S,Hedlund E,Chen X,Oberlin O,Lemmon G,Vadodaria B,Gut M,Mardis ER,Shurtleff S,Michon J,Gut I,Dyer M,Delattre O.Children's Research Hospital-Washington University Pediatric Cancer Genome Project and the International Cancer Genome Consortium.Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov2014;4:1342-53 PMCID:PMC4264969

[65] Crompton BD,Taylor-Weiner A,Kurek KC,Kiezun A,Shukla SA,Thorner AR,Lavarino C,McKenna A,Cibulskis K,Stojanov P,Ambrogio L,Seepo S,DeFelice M,Schwarz-Cruz Y,Rivera MN,Fleming MD,Getz G,Stegmaier K.The genomic landscape of pediatric Ewing sarcoma.Cancer Discov2014;4:1326-41

[66] Kovar H,Aryee DN,Ambros P,Windhager R.Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors.Oncogene1997;15:2225-32

[67] Tsuchiya T,Hinohara S,Nobori T.Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.Cancer Genet Cytogenet2000;120:91-8

[68] Wei G,de Alava E,Huvos AG,Healey JH.Prognostic impact of INK4A deletion in Ewing sarcoma.Cancer2000;89:793-9

[69] Maitra A,Weinberg AG.Aberrant expression of tumor suppressor proteins in the Ewing family of tumors.Arch Pathol Lab Med2001;125:1207-12

[70] Brownhill SC,Burchill SA.Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT.Br J Cancer2007;96:1914-23 PMCID:PMC2359978

[71] Honoki K,McEvoy M,Tsujiuchi T,Takakura Y.Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis.Cancer2007;110:1351-60

[72] Lerman DM,McIlvaine E,Huang D,Beeler N,Marina NM,Bridge JA,Randall RL.Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.Pediatr Blood Cancer2015;62:759-65 PMCID:PMC4376595

[73] Huang HY,Zhao Z,Huvos AG,Wexler LH,Meyers P.Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse.J Clin Oncol2005;23:548-58

[74] Solomon DA,Diaz-Martinez LA,Elkahloun AG,Toretsky JA,Shukla N,Samuels Y,Yu H,Waldman T.Mutational inactivation of STAG2 causes aneuploidy in human cancer.Science2011;333:1039-43 PMCID:PMC3374335

[75] Solomon DA,Waldman T.Cohesin gene mutations in tumorigenesis: from discovery to clinical significance.BMB Rep2014;47:299-310 PMCID:PMC4163871

[76] Lawrence MS,Mermel CH,Garraway LA,Meyerson M,Lander ES.Discovery and saturation analysis of cancer genes across 21 tumor types.Nature2014;505:495-501 PMCID:PMC4048962

[77] Mazumdar C,Xavy S,Reinisch A,Corces MR,Buenrostro JD,Thomas D,Hong WJ,Majeti R.Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation.Cell Stem Cell2015;17:675-88 PMCID:PMC4671831

[78] van der Lelij P,Jude J,Santos CP,Schlattl A,Schwentner R,Kovar H,Waldman T,Kraut N,Zuber J.Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts.Elife2017;6:e26980 PMCID:PMC5531830

[79] Sheffield NC,Klughammer J,Schönegger A,Hadler J,Guillemot D,Freneaux P,Bouvier R,Ambros IM,Sorz E,de álava E,Strunk D,Liegl-Atzwanger B,Leithner A,Terrier P,Michon J,Holter W,Dirksen U,Delattre O,Bock C.DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma.Nat Med2017;23:386-95 PMCID:PMC5951283

[80] Riggi N,Gillespie SM,Boulay G,Rossetti NE,Oksuz O,Formey A,Gymrek M,Deshpande V,Hornicek FJ,Stamenkovic I,Bernstein BE.EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.Cancer Cell2014;26:668-81 PMCID:PMC4492343

[81] Patel N,Chen X,Grady WM,Borinstein SC.DNA methylation and gene expression profiling of Ewing sarcoma primary tumors reveal genes that are potential targets of epigenetic inactivation.Sarcoma2012;2012:498472 PMCID:PMC3447379

[82] Alholle A,Gharanei S,Arrigoni E,Gentle D,Hiruma T,Grimer R,Latif F.Functional epigenetic approach identifies frequently methylated genes in Ewing sarcoma.Epigenetics2013;8:1198-204

[83] Huertas-Martínez J,Rello-Varona S,Almacellas-Rabaiget O,Garcia-Monclús S,Buj R,Sastre A,Sanjuan X,Moran S,Gallego S,García Del Muro X,Peinado MA,de Alava E,Esteller M.DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1.Cancer Lett2017;386:196-207

[84] Torchia EC,Rehg JE,Baker SJ.EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.Mol Cell Biol2007;27:7918-34 PMCID:PMC2169157

[85] Lin PP,Jin F,Deavers M,Lozano G.EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model.Cancer Res2008;68:8968-75 PMCID:PMC4167779

[86] Embree LJ,Hickstein DD.Ewing sarcoma fusion protein EWSR1/FLI1 interacts with EWSR1 leading to mitotic defects in zebrafish embryos and human cell lines.Cancer Res2009;69:4363-71 PMCID:PMC2766243

[87] Park H,Turner T,Azuma M.Loss of Ewing sarcoma EWS allele promotes tumorigenesis by inducing chromosomal instability in zebrafish.Sci Rep2016;6:32297 PMCID:PMC4997631

[88] Bacabac RG,Mullender MG,Van Loon JJ.Nitric oxide production by bone cells is fluid shear stress rate dependent.Biochem Biophys Res Commun2004;315:823-9

[89] Klein-Nulend J,Bakker AD.Mechanical loading and how it affects bone cells: the role of the osteocyte cytoskeleton in maintaining our skeleton.Eur Cell Mater2012;24:278-91

[90] Santoro M,Menegaz BA,Mikos AG.Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma.Proc Natl Acad Sci U S A2015;112:10304-9 PMCID:PMC4547215

[91] Santoro M,Lamhamedi-Cherradi SE,Wu D,Ludwig JA.Modeling stroma-induced drug resistance in a tissue-engineered tumor model of Ewing sarcoma.Tissue Eng Part A2017;23:80-9 PMCID:PMC5240012

[92] Marturano-Kruik A,Yaeger K,Chramiec A,Vunjak-Novakovic G.Biomechanical regulation of drug sensitivity in an engineered model of human tumor.Biomaterials2018;150:150-61

[93] Scotlandi K,Nanni P,Nicoletti G,Serra M,Picci P.Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice.Cancer Res1998;58:4127-31

[94] Vormoor J,Decker S,Schäfer KL,Rübe C,Jürgens H.Establishment of an in vivo model for pediatric Ewing tumors by transplantation into NOD/scid mice.Pediatr Res2001;49:332-41

[95] Franzius C,Poremba C,Schäfers K,Jürgens H,Schäfers M.Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model.Eur J Nucl Med Mol Imaging2006;33:1432-41

[96] Wang YX,Wang S,Pollock RE,Kleinerman E.Inhibiting platelet-derived growth factor β reduces Ewing's sarcoma growth and metastasis in a novel orthotopic human xenograft model.In Vivo2009;23:903-9

[97] Vormoor B,Batey MA,Wilson I,Sharma A,Hide IG,Vormoor J,Bacon CM.Development of a preclinical orthotopic xenograft model of Ewing sarcoma and other human malignant bone disease using advanced in vivo imaging.PLoS One2014;9:e85128 PMCID:PMC3883696

[98] Goldstein SD,Albert CM,Loeb DM.An orthotopic xenograft model with survival hindlimb amputation allows investigation of the effect of tumor microenvironment on sarcoma metastasis.Clin Exp Metastasis2015;32:703-15

[99] Hong SH,Galli S,Polk T,Mahajan A,Jenkins S,Connors K,Lu C,Rodriguez O,Albanese C.High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases.Oncotarget2015;6:7151-65 PMCID:PMC4466675

[100] Harris JC,Kajdacsy-Balla A,Chiu B.Sustained delivery of vincristine inside an orthotopic mouse sarcoma model decreases tumor growth.J Pediatr Surg2016;51:2058-62 PMCID:PMC5138133

[101] VAN Noord RA,Krook M,Hoenerhoff MJ,Lawlor ER,Newman EA.Tissue-directed implantation using ultrasound visualization for development of biologically relevant metastatic tumor xenografts.In Vivo2017;31:779-91 PMCID:PMC5656850

[102] Sirsi SR,Vlachos F,Hernandez SL,Johung TB,Reichstein AR,Wang A,Kandel JJ,Borden MA.Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.Ultrasound Med Biol2012;38:1019-29 PMCID:PMC3348332

[103] van der Ent W,Teunisse AF,Szuhai K,Hogendoorn PC.Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.J Pathol2014;233:415-24

[104] El-Naggar AM,Cheng H,Negri GL,Corkery DP,Mathers J,Kyle AH,LePard NE,Hajee S,Leprivier G,Minchinton AI,Delattre O,Dellaire G,Sorensen PH.Translational activation of HIF1α by YB-1 promotes sarcoma metastasis.Cancer Cell2015;27:682-97

[105] Franzetti GA,van der Ent W,Irondelle M,Dirksen U,de Pinieux G,Chavrier P.Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells.Oncogene2017;36:3505-14 PMCID:PMC5541267

[106] Oyama R,Yoshida A,Takai Y,Shiozawa K,Arai Y,Araki Y,Kawai A.Generation of novel patient-derived CIC-DUX4 sarcoma xenografts and cell lines.Sci Rep2017;7:4712 PMCID:PMC5498486

[107] Murakami T,Kiyuna T,Li Y,Igarashi K,DeLong JC,Hiroshima Y,Eckardt MA,Federman N,Chishima T,Bouvet M,Eilber FC.Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.Oncotarget2016;7:47556-64 PMCID:PMC5216960

[108] TK216 in Patients With Relapsed or Refractory Ewing Sarcoma. ClinicalTrials.gov Identifier: NCT02657005. Available from: https://clinicaltrials.gov/ct2/show/NCT02657005 [Last accessed on 23 May 2018].

[109] Gorthi A,Loranc E,Lawrence LA,Iniguez AB,Masamsetti VP,Lawlor ER,Stegmaier K,Chen Y.EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.Nature2018;555:387-91

[110] Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma. ClinicalTrials.gov Identifier: NCT01583543. Available from: https://clinicaltrials.gov/ct2/show/NCT01583543 [Last accessed on 23 May 2018].

[111] ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma. ClinicalTrials.gov Identifier: NCT02044120. Available from: https://clinicaltrials.gov/ct2/show/NCT02044120 [Last accessed on 23 May 2018].

[112] Kontny HU,Klein R,Mackall CL.Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.Cell Death Differ2001;8:506-14

[113] Lissat A,Tsokos M,Braun M,Fisch P,Long L,Mackall CL,Kontny U.Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.Am J Pathol2007;170:1917-30 PMCID:PMC1899433

[114] de Hooge AS,Santos SJ,Romeo S,Egeler RM,Melief CJ,Lankester AC.Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways.Clin Cancer Res2007;13:206-14

[115] Verhoeven DH,Mooiman EC,ten Dam MM,Melief CJ,Egeler RM,Schilham MW.NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.Mol Immunol2008;45:3917-25

[116] Pahl JH,Kwappenberg KM,van Tol MJ,Schilham MW.Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity.Cancer Immunol Immunother2013;62:1235-47

[117] Guiho R,Grisendi G,Chatelais M,Heymann D,Redini F.TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models.Int J Cancer2016;139:2802-11

[118] Berghuis D,Baelde HJ,Egeler RM,Hogendoorn PC.Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.J Pathol2011;223:347-57

[119] A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias. ClinicalTrials.gov Identifier: NCT01287104. Available from: https://clinicaltrials.gov/ct2/show/NCT01287104 [Last accessed on 23 May 2018].

[120] Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Sarcomas. ClinicalTrials.gov Identifier: NCT02409576. Available from: https://clinicaltrials.gov/ct2/show/NCT02409576 [Last accessed on 23 May 2018].

[121] Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors. ClinicalTrials.gov Identifier: NCT02100891. Available from: https://clinicaltrials.gov/ct2/show/NCT02100891 [Last accessed on 23 May 2018].

[122] Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors. ClinicalTrials.gov Identifier: NCT01807468. Available from: https://clinicaltrials.gov/ct2/show/NCT01807468 [Last accessed on 23 May 2018].

[123] Berghuis D,Vos HI,Kloess S,Egeler RM,Lankester AC.Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis.Clin Sarcoma Res2012;2:8 PMCID:PMC3351702

[124] Goodison S.The cancer testis antigen PRAME as a biomarker for solid tumor cancer management.Biomark Med2012;6:629-32

[125] Osterhoff C,Kirchhoff C.Cloning of a human epididymis-specific mRNA, HE6, encoding a novel member of the seven transmembrane-domain receptor superfamily.DNA Cell Biol1997;16:379-89

[126] Moreaux J,Hose D.STEAP1 is overexpressed in cancers: a promising therapeutic target.Biochem Biophys Res Commun2012;429:148-55

[127] Evans CH,Porter RM,Merghoub T,Robichaud K,Lessnick SL,Wells JW.EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.Clin Cancer Res2012;18:5341-51 PMCID:PMC3463738

[128] Berghuis D,Santos SJ,Wiertz EJ,van den Elsen PJ,Ottaviano L,Dirksen U,Mulder A,Egeler RM,Jordanova ES,Lankester AC.Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition.J Pathol2009;218:222-31

[129] Park JH,Gonen M,Sénéchal B,Sauter C,Santomasso B,Roshal M,Davila M,Sadelain M.Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.N Engl J Med2018;378:449-59

[130] Neelapu SS,Bartlett NL,Miklos DB,Braunschweig I,Siddiqi T,Timmerman JM,Friedberg JW,Goy A,Smith MR,Farooq U,Munoz J,Castro JE,Chavez JC,Komanduri KV,Jacobsen ED,Reagan P,Rossi J,Jiang Y,Elias M,Wiezorek J.Axicabtagene ciloleucel CAR T-cell therapy in refractory large b-cell lymphoma.N Engl J Med2017;377:2531-44 PMCID:PMC5882485

[131] Kailayangiri S,Meltzer J,Luecke A,Titze U,Landmeier S,Dirksen U,Gosheger G,Rossig C.The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.Br J Cancer2012;106:1123-33 PMCID:PMC3304425

[132] Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas. ClinicalTrials.gov Identifier: NCT03356782. Available from: https://clinicaltrials.gov/ct2/show/NCT03356782 [Last accessed on 23 May 2018].

[133] Town J,Harrison S,Bataille C,Zhang J.Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target.Proc Natl Acad Sci U S A2016;113:3603-8 PMCID:PMC4822608

[134] Ghisoli M,Schneider R,Lenarsky C,Kumar P,Roth A,Fletcher FA.Pilot trial of vigil immunotherapy in Ewing's sarcoma.J Clin Oncol2015;33 suppl 15:abstr10522

[135] Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer. ClinicalTrials.gov Identifier: NCT01061840. Available from: https://clinicaltrials.gov/ct2/show/NCT01061840. [Last accessed on 23 May 2018].

[136] Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma. ClinicalTrials.gov Identifier: NCT00101309. Available from: https://clinicaltrials.gov/ct2/show/NCT00101309. [Last accessed on 23 May 2018].

[137] A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma. ClinicalTrials.gov Identifier: NCT02511132. Available from: https://clinicaltrials.gov/ct2/show/NCT02511132. [Last accessed on 23 May 2018].

[138] Vakkila J,Michelow M.Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors.Clin Cancer Res2006;12:2049-54

[139] Long AH,Cui Y,Walker AJ,El-Etriby R,Tsokos MG,Mackall CL.Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas.Cancer Immunol Res2016;4:869-80 PMCID:PMC5050151